ENANTA PHARMACEUTICALS, INC (ENTA) Return on equity 2017–2025
ENANTA PHARMACEUTICALS, INC (ENTA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-179.3%FY2025 · since FY2017: 7.2% → -179.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -179.3% | -75.4 pp |
| FY2024 | -103.9% | -47.7 pp |
| FY2023 | -56.2% | -31.6 pp |
| FY2022 | -24.6% | -15.5 pp |
| FY2021 | -9.1% | -19.2 pp |
| FY2020 | 10.2% | -5.4 pp |
| FY2019 | 15.6% | +11.1 pp |
| FY2018 | 4.5% | -2.7 pp |
| FY2017 | 7.2% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice